About this trial

This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome, the research seeks to determine which biological factors predict disease progression and how these insights can inform precision prevention and treatment strategies for metabolic disorders.

Eligibility criteria

Qualifiers

Individuals (male or female) aged 20 years or older

Willing and able to provide written informed consent to participate in the study

Disqualifiers

Pregnant or breastfeeding women

Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis

Individuals currently undergoing active cancer treatment

Recipients of any organ transplantation

Trial design

Treatments tested in this trial

  • No intervention

Treatment groups

6,266 Participants
are divided into 1 treatment group

Locations

1
Chang Gung Memorial Hospitals, Linkou Taoyuan Taiwan

Sponsors and collaborators

Chang Gung Memorial Hospital

Lead sponsor